|
May 12, 2021
|
BioCryst Receives UK Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
|
|
|
May 06, 2021
|
BioCryst Reports First Quarter 2021 Financial Results and Upcoming Key Milestones
|
|
|
May 05, 2021
|
BioCryst to Present at Upcoming Investor Conferences
|
|
|
Apr 30, 2021
|
BioCryst Receives European Commission Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
|
|
|
Apr 22, 2021
|
BioCryst to Report First Quarter 2021 Financial Results on May 6
|
|
|
Apr 14, 2021
|
BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO™ (berotralstat) for Prophylactic Treatment of Hereditary Angioedema
|
|
|
Apr 07, 2021
|
BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference
|
|
|
Mar 22, 2021
|
BioCryst’s Oral Factor D Inhibitor, BCX9930, Advancing to Pivotal Trials in PNH Following Successful Proof of Concept Trial
|
|
|
Mar 19, 2021
|
BioCryst Appoints Helen Thackray, M.D., as Chief Research and Development Officer
|
|
|
Mar 15, 2021
|
BioCryst to Host Virtual R&D Day on March 22, 2021
|
|
